Video

Dr. Singh on Challenges in Leiomyosarcoma Treatment

Author(s):

Arun S. Singh, MD

In Partnership With:

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses the challenges of treating patients with leiomyosarcoma.

Arun S. Singh, MD, associate professor, Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, discusses the challenges of treating patients with leiomyosarcoma.

Many patients with leiomyosarcoma are diagnosed in later stages of disease. This issue partially stems from the overlap between leiomyosarcoma and fibroids, says Singh. Fibroids, which are smooth muscle growths, are a very prevalent problem in women. Leiomyosarcoma is a smooth muscle cancer, and many women who go in for surgery thinking they have fibroids, come out to find they have leiomyosarcoma.

Singh says that this is the biggest problem in deciding how to treat the disease, as surgery for fibroids differs greatly from surgery for leiomyosarcoma. Additionally, the issue of patients being diagnosed later in their disease course makes intervention more difficult.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center
Related Content
Aditya Bardia, MD, MPH, FASCO, of UCLA
October 15th 2024

TROP2 Offers Attractive Therapeutic Target in Breast Cancer and Other Solid Tumors

Aaron Lisberg, MD, assistant clinical professor, medicine, University of California, Los Angeles School of Medicine
August 1st 2024

Lisberg Lends Insight About the TROPION-Lung01 Trial of Dato-DXd in NSCLC

Adam E. Singer, MD, PhD, of UCLA Health
September 13th 2024

Cabozantinib/Nivolumab Combination Findings Further Inform RCC Care

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Adam E. Singer, MD, PhD, of UCLA Health
September 12th 2024

Histologic Features, Risk Help Reduce Uncertainties Around Frontline Treatment Selection in RCC

Ritu Salani, MD, director, Gynecologic Oncology, University of California Los Angeles
August 28th 2024

Novel Targets Facilitate Treatment Advances and Spur Further Questions in Endometrial Cancer